186 results
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
20 Mar 24
RepliCel announces a Letter of Intent for Asset Purchase Agreement
4:38pm
people in industrialized nations, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. These conditions, often
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
may, among other things, include the Company's:
belief that chronic tendon injuries resulting from sports-related or occupational overuse … of RCT-01 on patients suffering from chronic Achilles tendinosis in Canada and other countries are sufficient to support regulatory approvals to proceed
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
30 Nov 23
Condensed Consolidated Interim Financial Statements
1:05pm
focused on developing autologous cell therapies that treat functional cellular deficits including chronic tendon injuries, androgenetic alopecia and skin … -01 (NBDS Fibroblast Therapy - Treatment for Aging Skin), RCT-01 (NBDS Fibroblast Therapy - Treatment for Chronic Tendinosis) and any other product
6-K
EX-99.1
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
cellular deficits including chronic tendon injuries, androgenetic alopecia and skin aging.
The Company's corporate office and principal place … Products" defined as its RCS-01 (NBDS Fibroblast Therapy - Treatment for Aging Skin), RCT-01 (NBDS Fibroblast Therapy - Treatment for Chronic Tendinosis
6-K
EX-99.2
REPCF
Replicel Life Sciences Inc.
24 Oct 23
Condensed Consolidated Interim Financial Statements
11:10am
things, include the Company's:
belief that chronic tendon injuries resulting from sports-related or occupational overuse is a significant unmet medical … suffering from chronic Achilles tendinosis in Canada and other countries are sufficient to support regulatory approvals to proceed to a phase 2 trial
6-K
EX-99.1
jqbn0828lctrcge 34k
19 Oct 23
Current report (foreign)
1:45pm
6-K
EX-99.1
rvnpnww0api mi6
4 Oct 23
RepliCel Provides Default Status Update and Announces Shareholder Approval of Equity Incentive Plan
2:23pm
6-K
EX-99.2
k95ez6fmc8e btamui
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.1
ud3qsb clu
13 Sep 23
RepliCel Announces DermaPrecise™ Development Milestone, Updates Arbitration Proceedings
5:32pm
6-K
EX-99.1
x34m4iw iwby
7 Sep 23
Current report (foreign)
12:26pm
6-K
EX-99.1
iu3xt2 favexrcz9
29 Aug 23
RepliCel announces the passing of long time Chief Financial Officer Simon Ma; David Kwok is appointed Chief Financial Officer
1:14pm
6-K
EX-99.2
rew6lmp
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.4
x8ro iv2r7r
17 Aug 23
Annual General and Special Meeting
11:22am
6-K
EX-99.1
7en82rx8rhpdicb6glgu
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.2
6zgzx1rsq i1u30rjauh
30 May 23
Condensed Consolidated Interim Financial Statements
5:40pm
6-K
EX-99.1
5tn6rchrxozbh6r1
18 May 23
RepliCel Applies to Extend Warrant and Stock Option Expiry Dates and Announces Grant of Stock Options
1:58pm
6-K
EX-99.1
nj3pl6v
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.2
enf s8aoqd
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm
6-K
EX-99.5
smpxigy
29 Nov 22
Condensed Consolidated Interim Financial Statements
6:44pm